Impact of Food and Drug Administration Regulations on the Performance of Guideline-Recommended Pathways With an Approved Point-of-Care High-Sensitivity Cardiac Troponin I Assay.
- DOI
- 10.1161/jaha.124.039164
- Published
- 2025 Mar 18
- Container
- Journal of the American Heart Association
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1161/jaha.124.039164,
title = {Impact of Food and Drug Administration Regulations on the Performance of Guideline-Recommended Pathways With an Approved Point-of-Care High-Sensitivity Cardiac Troponin I Assay.},
author = {Koechlin L and Boeddinghaus J and Lopez-Ayala P and Bianchi CL and Nestelberger T and Wildi K and Miró Ò and Christ M and Rentsch K and Mahfoud F and Mueller C and APACE investigators †},
year = {2025},
journal = {Journal of the American Heart Association},
doi = {10.1161/jaha.124.039164},
url = {https://doi.org/10.1161/jaha.124.039164}
}RIS
TY - JOUR TI - Impact of Food and Drug Administration Regulations on the Performance of Guideline-Recommended Pathways With an Approved Point-of-Care High-Sensitivity Cardiac Troponin I Assay. AU - Koechlin L AU - Boeddinghaus J AU - Lopez-Ayala P AU - Bianchi CL AU - Nestelberger T AU - Wildi K AU - Miró Ò AU - Christ M AU - Rentsch K AU - Mahfoud F AU - Mueller C AU - APACE investigators † PY - 2025 JO - Journal of the American Heart Association DO - 10.1161/jaha.124.039164 UR - https://doi.org/10.1161/jaha.124.039164 ER -
APA
L, K., J, B., P, L., CL, B., T, N., K, W., Ò, M., M, C., K, R., F, M., C, M., & †, A. I. (2025). Impact of Food and Drug Administration Regulations on the Performance of Guideline-Recommended Pathways With an Approved Point-of-Care High-Sensitivity Cardiac Troponin I Assay.. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039164
Source records
- pubmed · retrieved 2026-09-27T15:02:14.974Z